Business Description
ExpreS2ion Biotech Holding AB
ISIN : SE0023261292
Compare
Compare
Traded in other countries / regions
EXPRS2.Sweden5JD0.Germany IPO Date
2020-08-06Description
ExpreS2ion Biotech Holding AB has developed a technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. The company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with research institutions and companies.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 213.42 | |||||
| Equity-to-Asset | 0.66 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0.27 | |||||
| Beneish M-Score | -1.5 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -4.8 | |||||
| 3-Year EBITDA Growth Rate | -30.3 | |||||
| 3-Year EPS without NRI Growth Rate | -22.9 | |||||
| 3-Year FCF Growth Rate | -51.5 | |||||
| 3-Year Book Growth Rate | -25 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 15.72 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 88.28 | |||||
| 9-Day RSI | 70.37 | |||||
| 14-Day RSI | 58.4 | |||||
| 3-1 Month Momentum % | 27.24 | |||||
| 6-1 Month Momentum % | -25.07 | |||||
| 12-1 Month Momentum % | -74.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.85 | |||||
| Quick Ratio | 2.85 | |||||
| Cash Ratio | 2.3 | |||||
| Days Sales Outstanding | 122.25 | |||||
| Days Payable | 222.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.9 | |||||
| Shareholder Yield % | 2.99 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -15.58 | |||||
| Operating Margin % | -1946.95 | |||||
| Net Margin % | -965.23 | |||||
| FCF Margin % | -1259.29 | |||||
| ROE % | -52.76 | |||||
| ROA % | -36.54 | |||||
| ROIC % | -175.24 | |||||
| 3-Year ROIIC % | 2317.6 | |||||
| ROC (Joel Greenblatt) % | -2065.3 | |||||
| ROCE % | -58.8 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.52 | |||||
| PB Ratio | 0.69 | |||||
| Price-to-Tangible-Book | 0.74 | |||||
| EV-to-EBIT | 0.4 | |||||
| EV-to-Forward-EBIT | -0.08 | |||||
| EV-to-EBITDA | 0.42 | |||||
| EV-to-Forward-EBITDA | -0.08 | |||||
| EV-to-Revenue | -4.46 | |||||
| EV-to-Forward-Revenue | 0.38 | |||||
| EV-to-FCF | 0.71 | |||||
| Price-to-GF-Value | 0.18 | |||||
| Price-to-Net-Current-Asset-Value | 0.84 | |||||
| Price-to-Net-Cash | 1.21 | |||||
| Earnings Yield (Greenblatt) % | 249.79 | |||||
| FCF Yield % | -77.08 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ExpreS2ion Biotech Holding AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.312 | ||
| EPS (TTM) (€) | -20.214 | ||
| Beta | 4.11 | ||
| 3-Year Sharpe Ratio | -0.43 | ||
| 3-Year Sortino Ratio | -0.74 | ||
| Volatility % | 190.39 | ||
| 14-Day RSI | 58.4 | ||
| 14-Day ATR (€) | 0.121384 | ||
| 20-Day SMA (€) | 1.7766 | ||
| 12-1 Month Momentum % | -74.47 | ||
| 52-Week Range (€) | 1.564 - 12.154506 | ||
| Shares Outstanding (Mil) | 2.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ExpreS2ion Biotech Holding AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ExpreS2ion Biotech Holding AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
ExpreS2ion Biotech Holding AB Frequently Asked Questions
What is ExpreS2ion Biotech Holding AB(FRA:5JD0)'s stock price today?
The current price of FRA:5JD0 is €2.14. The 52 week high of FRA:5JD0 is €12.15 and 52 week low is €1.56.
When is next earnings date of ExpreS2ion Biotech Holding AB(FRA:5JD0)?
The next earnings date of ExpreS2ion Biotech Holding AB(FRA:5JD0) is 2025-02-06.
Does ExpreS2ion Biotech Holding AB(FRA:5JD0) pay dividends? If so, how much?
ExpreS2ion Biotech Holding AB(FRA:5JD0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers